A citation-based method for searching scientific literature

Rory M Shallis, Rong Wang, Amy Davidoff, Xiaomei Ma, Nikolai A Podoltsev, Amer M Zeidan. Blood Rev 2020
Times Cited: 37







List of co-cited articles
308 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.
Daniel A Arber, Attilio Orazi, Robert Hasserjian, Jürgen Thiele, Michael J Borowitz, Michelle M Le Beau, Clara D Bloomfield, Mario Cazzola, James W Vardiman. Blood 2016
40

New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes, Brigitte Dupriez, Arturo Pereira, Francesco Passamonti, John T Reilly, Enrica Morra, Alessandro M Vannucchi, Ruben A Mesa, Jean-Loup Demory, Giovanni Barosi,[...]. Blood 2009
848
29

Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis.
Ayalew Tefferi, Paola Guglielmelli, Dirk R Larson, Christy Finke, Emnet A Wassie, Lisa Pieri, Naseema Gangat, Rajmonda Fjerza, Alem A Belachew, Terra L Lasho,[...]. Blood 2014
424
27

The 2016 WHO classification and diagnostic criteria for myeloproliferative neoplasms: document summary and in-depth discussion.
Tiziano Barbui, Jürgen Thiele, Heinz Gisslinger, Hans Michael Kvasnicka, Alessandro M Vannucchi, Paola Guglielmelli, Attilio Orazi, Ayalew Tefferi. Blood Cancer J 2018
254
21

Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet.
Tiziano Barbui, Ayalew Tefferi, Alessandro M Vannucchi, Francesco Passamonti, Richard T Silver, Ronald Hoffman, Srdan Verstovsek, Ruben Mesa, Jean-Jacques Kiladjian, Rȕdiger Hehlmann,[...]. Leukemia 2018
285
18

Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study.
A Tefferi, E Rumi, G Finazzi, H Gisslinger, A M Vannucchi, F Rodeghiero, M L Randi, R Vaidya, M Cazzola, A Rambaldi,[...]. Leukemia 2013
399
18


A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Richard S Levy, Vikas Gupta, John F DiPersio, John V Catalano, Michael Deininger, Carole Miller, Richard T Silver,[...]. N Engl J Med 2012
18

Long-term survival in patients treated with ruxolitinib for myelofibrosis: COMFORT-I and -II pooled analyses.
Srdan Verstovsek, Jason Gotlib, Ruben A Mesa, Alessandro M Vannucchi, Jean-Jacques Kiladjian, Francisco Cervantes, Claire N Harrison, Ronald Paquette, William Sun, Ahmad Naim,[...]. J Hematol Oncol 2017
147
16

GIPSS: genetically inspired prognostic scoring system for primary myelofibrosis.
Ayalew Tefferi, Paola Guglielmelli, Maura Nicolosi, Francesco Mannelli, Mythri Mudireddy, Niccolo Bartalucci, Christy M Finke, Terra L Lasho, Curtis A Hanson, Rhett P Ketterling,[...]. Leukemia 2018
147
16

Myeloproliferative Neoplasms.
Jerry L Spivak. N Engl J Med 2017
195
16

Incidence of myeloproliferative neoplasms - trends by subgroup and age in a population-based study in Sweden.
M Hultcrantz, A Ravn Landtblom, B Andréasson, J Samuelsson, P W Dickman, S Y Kristinsson, M Björkholm, T M-L Andersson. J Intern Med 2020
17
35

Incidence and patient survival of myeloproliferative neoplasms and myelodysplastic/myeloproliferative neoplasms in the United States, 2001-12.
Samer A Srour, Susan S Devesa, Lindsay M Morton, David P Check, Rochelle E Curtis, Martha S Linet, Graça M Dores. Br J Haematol 2016
103
16

Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
Odile Moulard, Jyotsna Mehta, Jon Fryzek, Robert Olivares, Usman Iqbal, Ruben A Mesa. Eur J Haematol 2014
122
16

Mutations and prognosis in primary myelofibrosis.
A M Vannucchi, T L Lasho, P Guglielmelli, F Biamonte, A Pardanani, A Pereira, C Finke, J Score, N Gangat, C Mannarelli,[...]. Leukemia 2013
516
13

Cardiovascular events and intensity of treatment in polycythemia vera.
Roberto Marchioli, Guido Finazzi, Giorgina Specchia, Rossella Cacciola, Riccardo Cavazzina, Daniela Cilloni, Valerio De Stefano, Elena Elli, Alessandra Iurlo, Roberto Latagliata,[...]. N Engl J Med 2013
466
13

Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia.
Gabriela M Baerlocher, Elisabeth Oppliger Leibundgut, Oliver G Ottmann, Gary Spitzer, Olatoyosi Odenike, Michael A McDevitt, Alexander Röth, Michael Daskalakis, Bart Burington, Monic Stuart,[...]. N Engl J Med 2015
131
13

Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study.
Francesco Passamonti, Martin Griesshammer, Francesca Palandri, Miklos Egyed, Giulia Benevolo, Timothy Devos, Jeannie Callum, Alessandro M Vannucchi, Serdar Sivgin, Caroline Bensasson,[...]. Lancet Oncol 2017
150
13

Targeted deep sequencing in polycythemia vera and essential thrombocythemia.
Ayalew Tefferi, Terra L Lasho, Paola Guglielmelli, Christy M Finke, Giada Rotunno, Yoseph Elala, Annalisa Pacilli, Curtis A Hanson, Alessandro Pancrazzi, Rhett P Ketterling,[...]. Blood Adv 2016
187
13

Ruxolitinib versus standard therapy for the treatment of polycythemia vera.
Alessandro M Vannucchi, Jean Jacques Kiladjian, Martin Griesshammer, Tamas Masszi, Simon Durrant, Francesco Passamonti, Claire N Harrison, Fabrizio Pane, Pierre Zachee, Ruben Mesa,[...]. N Engl J Med 2015
514
13

LSD1 Inhibition Prolongs Survival in Mouse Models of MPN by Selectively Targeting the Disease Clone.
Jonas S Jutzi, Maria Kleppe, Jennifer Dias, Hans Felix Staehle, Kaitlyn Shank, Julie Teruya-Feldstein, Sudheer Madan Mohan Gambheer, Christine Dierks, Hugh Y Rienhoff, Ross L Levine,[...]. Hemasphere 2018
55
13

3023 Mayo Clinic Patients With Myeloproliferative Neoplasms: Risk-Stratified Comparison of Survival and Outcomes Data Among Disease Subgroups.
Natasha Szuber, Mythri Mudireddy, Maura Nicolosi, Domenico Penna, Rangit R Vallapureddy, Terra L Lasho, Christy Finke, Kebede H Begna, Michelle A Elliott, C Christopher Hook,[...]. Mayo Clin Proc 2019
57
13

Risk for Arterial and Venous Thrombosis in Patients With Myeloproliferative Neoplasms: A Population-Based Cohort Study.
Malin Hultcrantz, Magnus Björkholm, Paul W Dickman, Ola Landgren, Åsa R Derolf, Sigurdur Y Kristinsson, Therese M L Andersson. Ann Intern Med 2018
116
13

Somatic mutations of calreticulin in myeloproliferative neoplasms.
Thorsten Klampfl, Heinz Gisslinger, Ashot S Harutyunyan, Harini Nivarthi, Elisa Rumi, Jelena D Milosevic, Nicole C C Them, Tiina Berg, Bettina Gisslinger, Daniela Pietra,[...]. N Engl J Med 2013
13

A gain-of-function mutation of JAK2 in myeloproliferative disorders.
Robert Kralovics, Francesco Passamonti, Andreas S Buser, Soon-Siong Teo, Ralph Tiedt, Jakob R Passweg, Andre Tichelli, Mario Cazzola, Radek C Skoda. N Engl J Med 2005
13

Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial.
Srdan Verstovsek, Ruben A Mesa, Jason Gotlib, Vikas Gupta, John F DiPersio, John V Catalano, Michael W N Deininger, Carole B Miller, Richard T Silver, Moshe Talpaz,[...]. J Hematol Oncol 2017
226
13

Somatic CALR mutations in myeloproliferative neoplasms with nonmutated JAK2.
J Nangalia, C E Massie, E J Baxter, F L Nice, G Gundem, D C Wedge, E Avezov, J Li, K Kollmann, D G Kent,[...]. N Engl J Med 2013
13

JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis.
Linda M Scott, Wei Tong, Ross L Levine, Mike A Scott, Philip A Beer, Michael R Stratton, P Andrew Futreal, Wendy N Erber, Mary Frances McMullin, Claire N Harrison,[...]. N Engl J Med 2007
901
13

Myeloproliferative neoplasms: trends in incidence, prevalence and survival in Norway.
Christina Roaldsnes, René Holst, Henrik Frederiksen, Waleed Ghanima. Eur J Haematol 2017
26
19

Changing incidence of myeloproliferative neoplasms in Australia, 2003-2014.
Peter D Baade, David M Ross, Lesley A Anderson, Cecily Forsyth, Lin Fritschi. Am J Hematol 2019
12
41

JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Claire Harrison, Jean-Jacques Kiladjian, Haifa Kathrin Al-Ali, Heinz Gisslinger, Roger Waltzman, Viktoriya Stalbovskaya, Mari McQuitty, Deborah S Hunter, Richard Levy, Laurent Knoops,[...]. N Engl J Med 2012
13

MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis.
Paola Guglielmelli, Terra L Lasho, Giada Rotunno, Mythri Mudireddy, Carmela Mannarelli, Maura Nicolosi, Annalisa Pacilli, Animesh Pardanani, Elisa Rumi, Vittorio Rosti,[...]. J Clin Oncol 2018
238
10

Imetelstat, a telomerase inhibitor, differentially affects normal and malignant megakaryopoiesis.
G Mosoyan, T Kraus, F Ye, K Eng, J D Crispino, R Hoffman, C Iancu-Rubin. Leukemia 2017
26
15

Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms.
Alessandro Prestipino, Alica J Emhardt, Konrad Aumann, David O'Sullivan, Sivahari P Gorantla, Sandra Duquesne, Wolfgang Melchinger, Lukas Braun, Slavica Vuckovic, Melanie Boerries,[...]. Sci Transl Med 2018
128
10

Ruxolitinib and interferon-α2 combination therapy for patients with polycythemia vera or myelofibrosis: a phase II study.
Anders Lindholm Sørensen, Stine Ulrik Mikkelsen, Trine Alma Knudsen, Mads Emil Bjørn, Christen Lykkegaard Andersen, Ole Weis Bjerrum, Nana Brochmann, Dustin Andersen Patel, Lise Mette Rahbek Gjerdrum, Daniel El Fassi,[...]. Haematologica 2020
37
10

Ropeginterferon alfa-2b versus standard therapy for polycythaemia vera (PROUD-PV and CONTINUATION-PV): a randomised, non-inferiority, phase 3 trial and its extension study.
Heinz Gisslinger, Christoph Klade, Pencho Georgiev, Dorota Krochmalczyk, Liana Gercheva-Kyuchukova, Miklos Egyed, Viktor Rossiev, Petr Dulicek, Arpad Illes, Halyna Pylypenko,[...]. Lancet Haematol 2020
122
10

Persistent leukocytosis in polycythemia vera is associated with disease evolution but not thrombosis.
Lukas Ronner, Nikolai Podoltsev, Jason Gotlib, Mark L Heaney, Andrew T Kuykendall, Casey O'Connell, Jamile Shammo, Angela G Fleischman, Robyn M Scherber, Ruben Mesa,[...]. Blood 2020
33
12

Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms.
Jelena D Milosevic Feenstra, Harini Nivarthi, Heinz Gisslinger, Emilie Leroy, Elisa Rumi, Ilyas Chachoua, Klaudia Bagienski, Blanka Kubesova, Daniela Pietra, Bettina Gisslinger,[...]. Blood 2016
173
10

Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.
Koen Schepers, Eric M Pietras, Damien Reynaud, Johanna Flach, Mikhail Binnewies, Trit Garg, Amy J Wagers, Edward C Hsiao, Emmanuelle Passegué. Cell Stem Cell 2013
421
10


The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.
James W Vardiman, Jüergen Thiele, Daniel A Arber, Richard D Brunning, Michael J Borowitz, Anna Porwit, Nancy Lee Harris, Michelle M Le Beau, Eva Hellström-Lindberg, Ayalew Tefferi,[...]. Blood 2009
10

Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis.
C N Harrison, A M Vannucchi, J-J Kiladjian, H K Al-Ali, H Gisslinger, L Knoops, F Cervantes, M M Jones, K Sun, M McQuitty,[...]. Leukemia 2016
288
10

MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients.
Animesh D Pardanani, Ross L Levine, Terra Lasho, Yana Pikman, Ruben A Mesa, Martha Wadleigh, David P Steensma, Michelle A Elliott, Alexandra P Wolanskyj, William J Hogan,[...]. Blood 2006
768
10

Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations.
Francesco Passamonti, Chiara Elena, Susanne Schnittger, Radek C Skoda, Anthony R Green, François Girodon, Jean-Jacques Kiladjian, Mary Frances McMullin, Marco Ruggeri, Carles Besses,[...]. Blood 2011
150
10

How common are myeloproliferative neoplasms? A systematic review and meta-analysis.
Glen J Titmarsh, Andrew S Duncombe, Mary Frances McMullin, Michael O'Rorke, Ruben Mesa, Frank De Vocht, Sarah Horan, Lin Fritschi, Mike Clarke, Lesley A Anderson. Am J Hematol 2014
107
10

Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study.
Malin Hultcrantz, Sigurdur Yngvi Kristinsson, Therese M-L Andersson, Ola Landgren, Sandra Eloranta, Asa Rangert Derolf, Paul W Dickman, Magnus Björkholm. J Clin Oncol 2012
146
10

Real world epidemiology of myeloproliferative neoplasms: a population based study in Korea 2004-2013.
Ja Min Byun, Young Jin Kim, Taemi Youk, John Jeongseok Yang, Jongha Yoo, Tae Sung Park. Ann Hematol 2017
17
23

Survival patterns in United States (US) medicare enrollees with non-CML myeloproliferative neoplasms (MPN).
Gregory L Price, Keith L Davis, Sudeep Karve, Gerhardt Pohl, Richard A Walgren. PLoS One 2014
39
10

A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment).
Francesco Passamonti, Francisco Cervantes, Alessandro Maria Vannucchi, Enrica Morra, Elisa Rumi, Arturo Pereira, Paola Guglielmelli, Ester Pungolino, Marianna Caramella, Margherita Maffioli,[...]. Blood 2010
618
10

The impact of myeloproliferative neoplasms (MPNs) on patient quality of life and productivity: results from the international MPN Landmark survey.
Claire N Harrison, Steffen Koschmieder, Lynda Foltz, Paola Guglielmelli, Tina Flindt, Michael Koehler, Jonathan Mathias, Norio Komatsu, Robert N Boothroyd, Amber Spierer,[...]. Ann Hematol 2017
58
10


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.